FY2029 Earnings Forecast for TYRA Issued By Wedbush

Tyra Biosciences, Inc. (NASDAQ:TYRA) – Wedbush issued their FY2029 EPS estimates for Tyra Biosciences in a report issued on Friday, March 28th. Wedbush analyst R. Driscoll expects that the company will post earnings per share of ($0.91) for the year. Wedbush has a “Outperform” rating and a $30.00 price target on the stock. The consensus estimate for Tyra Biosciences’ current full-year earnings is ($1.57) per share.

Tyra Biosciences (NASDAQ:TYRA) last announced its earnings results on Thursday, March 27th. The company reported ($0.43) EPS for the quarter, topping the consensus estimate of ($0.48) by $0.05.

Other analysts also recently issued reports about the company. HC Wainwright reiterated a “buy” rating and set a $30.00 target price on shares of Tyra Biosciences in a research report on Monday. UBS Group started coverage on Tyra Biosciences in a research note on Tuesday, January 7th. They issued a “buy” rating and a $28.00 price target for the company. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $30.83.

Tyra Biosciences Trading Down 4.8 %

Shares of TYRA stock opened at $9.30 on Monday. The stock has a 50 day simple moving average of $12.32 and a 200 day simple moving average of $16.22. Tyra Biosciences has a 1 year low of $9.05 and a 1 year high of $29.60. The stock has a market cap of $470.61 million, a P/E ratio of -5.78 and a beta of 1.09.

Institutional Trading of Tyra Biosciences

Large investors have recently bought and sold shares of the business. KLP Kapitalforvaltning AS bought a new position in Tyra Biosciences in the 4th quarter valued at approximately $31,000. US Bancorp DE bought a new position in shares of Tyra Biosciences in the 4th quarter valued at $50,000. BNP Paribas Financial Markets acquired a new stake in shares of Tyra Biosciences during the 4th quarter valued at $60,000. Aquatic Capital Management LLC bought a new stake in Tyra Biosciences during the 4th quarter worth $64,000. Finally, Wells Fargo & Company MN grew its position in Tyra Biosciences by 51.7% during the 4th quarter. Wells Fargo & Company MN now owns 9,493 shares of the company’s stock worth $132,000 after acquiring an additional 3,236 shares during the last quarter. 84.14% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, Director Nina S. Kjellson sold 5,401 shares of the business’s stock in a transaction on Wednesday, February 5th. The stock was sold at an average price of $13.76, for a total transaction of $74,317.76. Following the completion of the transaction, the director now owns 443,885 shares of the company’s stock, valued at approximately $6,107,857.60. The trade was a 1.20 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders sold 21,998 shares of company stock worth $344,818 over the last three months. Insiders own 15.40% of the company’s stock.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.